ANAFRONIL 25MG 30TAB

36.00 EGP

one coated tablet contains 25 mg of clomipramine hydrochloride .

ANAFRONIL 25MG 30TAB; clomipramine, antidepressants .

ACTIVE-INGREDIENT OF ANAFRONIL 25MG 30TAB

one coated tablet contains 25 mg of clomipramine hydrochloride .

INDICATION OF ANAFRONIL 25MG 30TAB

adults : treatment of depressive states of varying aetiology and symptomatology , e.g . Endogenous , reactive , neurotic , organic , masked , and invoutional forms of depression , depression associated with schizophrenia and personality disorders . depressive syndrome due to presentility or senility , to chronic painful conditions , and to chronic somatic diseases , depressive mood disorders of a reactive , neurotic , or psychopathic nature obsessive-compulsive syndromes . phobias and panic attacks cataplexy accompanying narcolepsy . choronic painful conditions . – children and adolescents : obsessive -compulsive syndromes noctumal enuresis ( only in patients over the age of 5 years and if organic causes have been excluded ) . when initiating clomipramine for noctamal enuresis to children and adolescents . careful consideration should be given to the benefits verus the risks for the individual , potential alternative therapies should be considered . no experience is available in children younger than 5 years of age . in children and adolescents , there is not sufficient evidence of safety and efficacy of anafronil in the treatment of depressive states of varying aetiology and symptomatology , phobias and panic attacks , cataplexy accompanying narcolepsy and choronic painful conditions . the use of anafronil in children and adolescents ( 0-17 years of age ) in these indications is therefore not recommended .

DOSAGE OF ANAFRONIL 25MG 30TAB

Follow all directions given to you by your pharmacist or doctor carefully . They may differ from the information contained in this leaflet

Ask your pharmacist or doctor for help if you do not understand the instructions on the box .

The recommended dose is : –

before initiating treatment with anafronil , hypokalemia should be treated . The dosage should be adapted to the individual patient’s condition . The aim is to achieve an optimum effect while keeping the doses as low as possible and increasing them cautiously . after a response has been obtained , maintainance should be adapted to the individual patient’s condition . The aim is to achieve an optimum effect while keeping the doses as low as possible and increasing them cautiously . after a response has been obtained , maintainance therapy should be continued at the optimum dose to avoid relapse . patients with a history of recurrent depression require maintainance treatment for a longer duration . duration of maintainance treatment and need for further treatment should be reviewed periodically . as a precaution against possible OTc prolongation and serotonergic toxicity adherence to the recommended doses of anafronil is advised and any increase in dose should be made with caution if drugs that prolong QT interval or other serotonergic agents are co-administered . abrupt discontinuation of anafronil therapy should be avoided because of possible withdrawl symptoms . therefore, dosage should be stopped gradually after regular use for long duration and the patient should be monitored carefully when anafronil therapy is discontinued , immediate release formulations ( coated tablets , capsules ) and sustained-release tablets can be used inter-changeably in equivalent doses . – depression , obsessive – compulsive syndromes , and phobias : start treatment with 50 – 75 mg/ day ( 1 coated tablet of 25 mg 2-3 times daily or 1 sustained-release tablet of 75 mg once daily ( preferably in the evening ) . raise the daily dosage stepwise , e.g. 25 mg every few days , ( depending on how the medication is tolerated ) to 100-150 mg during the first week of treatment . in sevre cases this dosage can be increased up to a maximum of 250 mg daily . once there is a distinic improvement , adjust the daily dosage to a maintance level of about 50-100 mg . – panic attacks , agoraphobia : start with 10 mg daily , depending on how the medication is tolerated , raise the dosage until the desired response is obtained . the daily dosage required varies greathly from patient to patient and lies between 25 to 100 mg . if necessary it can be increased to 150 mg . it is advisable for treatment not to be discontinued for at least 6 months and for the maintainance dose to be reduced slowly during this time . – cataplexy accompanying narcolepsy : daily dose of 25-75 mg . – chronic painful conditions : the dosage must be individualised ( 10-50 mg daily ) , while taking account of concomitant analgesic medication ( and of the possiblity of reducing use of analgesics ) . – dosage and administration in spesial populations : – geriatric patients ( aged 65 years and older ) : elderly patients generally show a stronger response to anafronil than patients of intermediate age groups , anafronil should be used with caution in elderly patients and doses should be increased cautiously . start treatment with 10 mg daily . gradually raise the dosage to an optimum level of 30-50 mg daily , which should be reached after about 10 days and then maintained until the end of treatment . . – children and adolescents : adolescents generally show a stronger response to anafronil than patients of intermediate age groups , anafronil should be used with caution in elderly patients and doses should be increased cautiously . – obsessive -compulsive syndromes : the starting dose is 25 mg and should be gradually increased ( also given in divided doses ) during the first 2 weeks , as tolerated , up to a daily maximum of 3 mg/kg or 100 mg , whichever is smaller . thereafter , the dosage may be increased gradually over the next several weeks up to a daily maximum of 3 mg/kg or 200 mg , whichever is smaller . – nocturnal enuresis : intial daily dose for first one week in children aged : 5-8 years , 20-30 mg . – 9-12 years , 25-50 mg . – above 12 years , 25-75 mg . subsequently , higher doses can be given to the patients who do not respond fully to the lower doses . the coated tablets should normally be given in a single dose after the evening meal , but children who wet their beds early in the night should be given part of the dose beforehand ( at 4 p.m ) . once the desired response has been achieved , treatment should be continued ( for 1-3 months ) and the dose gradually reduced . no experience is available in children under 5 years . – renal impairment : anafronil should be given with caution in patients with renal impairment . hepatic impairment : anafronil should be given with caution in patients with hepatic impairment . – method of administration : the method of administration ( oral or parenteral ) should be adapted to the individual patient’s condition . the sustained-release tablets should be swallowed whole . the divitabs ( sustained-release tablets divisible ) can be halved , allowing the dosage to be adapted individually , but they should not be chewed . anafronil can be administered with or without food .

OVER-DOSAGE OF ANAFRONIL 25MG 30TAB

the signs and symptoms of overdose with anafronil are similar to those reported with other tricyclic antidepressants . Cardiac abnormalities and neurological disturbances are the main complications . In children , accidental ingestion of any amount should be regarded as serious and potentially fetal . rare cases of pharmacobezoar , of varing severity including fetal outcome , have been reported in association with overdose of sustained release antafronil . the pharmacobezoar may be radiopaque , faciliting radiologic ( x-ray or ct scan ) confirmation but can not exclude the diagnosis . the formation of pharmacobezoar may cause slow but continual release and absorption of clomipramine which may lead to overdose complications , including death , hours after drug ingestion and initial treatment with gastric lavage and achieved charcoal . since gastric lavage may be ineffective and could further increase systemic drug levels , consideration should be given to physical removal of the pharmacobezoar by andoscopy or surgery in selected patients . since these cases are rare , there is insufficient clinical data regarding optimal treatment which should take into account the size and location of the pharmacobezoar , patient symptoms and condition and drug levels .

CONTRA-INDICATION OF ANAFRONIL 25MG 30TAB

known hypersensitivity to clomipramine or any of the excipients , or cross-sensitivity to tricyclic antidepressants of the dibenzazepine group . Anafronil must not be given in combination , or within 14 days before or after treatment , with a MAO inhibitor . the concomitant treatment with selective , reversible MAO-A inhibitors , such as moclobemide , is also contraindicated . recent myocardial infarction , congential long QT syndrome .

STORAGE OF ANAFRONIL 25MG 30TAB

protect from moisure .
PACK OF ANAFRONIL 25MG 30TAB

ANAFRONIL 25MG 30TAB MANUFACTURED BY
NOVARTIS PHARMA AG , BASEL , SWITZERLAND

https://www.drugs.com/mtm/clomipramine.html

https://www.gardeniapharmacy.com/category/medicine-2/

Form

Gender

How to use

Reviews

There are no reviews yet.

Show reviews in all languages (1)

Be the first to review “ANAFRONIL 25MG 30TAB”

Your email address will not be published. Required fields are marked *

Shopping Cart
Don`t copy text!
Scroll to Top
Open chat